LBRX

LBD

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$60.00

Analysis reference price unavailable

Analysis 2026-09-24 · RankAlpha Sentiment Codex

Most likely

Base case

45%

Probability

Target price

$33.00

Analysis reference price unavailable

Analysis 2026-09-24 · RankAlpha Sentiment Codex

B-

Bear case

30%

Probability

Target price

$15.00

Analysis reference price unavailable

Analysis 2026-09-24 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-09-24

AI commentary

Primary evidence supports a specific clinical calendar, but external coverage is low. The recent takeover-themed headline is speculation, not a transaction catalyst. No verified post-release price reaction, analyst revisions, social coverage, options skew, short interest or employee score is available; zero values above denote unavailable data, not neutral measurements. The deterministic prior remains negative despite strong source quality.

RankAlpha Sentiment Codex - 2026-09-24

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2027-03-31catalystAdjunctive MDD program initiationMedium impact

Management expects to start a Phase 2 LB-102 trial in adjunctive major depressive disorder in early 2027, with data expected in the first half of 2029. Initiation would demonstrate pipeline execution, not clinical success. [#SEC-8K-2026-08-11]

2027-06-30eventNOVA-2 Phase 3 schizophrenia readoutHigh impact

Faster-than-expected enrollment moved the company's projected LB-102 topline readout to the first half of 2027, ahead of prior guidance. The result is the principal binary value driver. [#SEC-8K-2026-08-11]

2027-12-31eventPotential FDA pre-NDA meetingHigh impact

The company plans to seek a pre-NDA meeting in the second half of 2027 after NOVA-2 topline data; its significance depends on the trial outcome. [#SEC-8K-2026-08-11]

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-09-24 • Updated nightlySource: Internal modelMethodology